
GOSS Stock Forecast & Price Target
GOSS Analyst Ratings
Bulls say
Gossamer Bio is moving towards a potential NDA submission and 3Q27 approval for its lead product seralutinib in pulmonary arterial hypertension (PAH), supported by positive data from its Phase 3 trial (PROSERA) and a successful in-person pre-NDA meeting with the FDA. The company is also addressing its balance sheet overhang through an exchange offer to reduce its outstanding convertible debt, further strengthening its financial position. While there remain risks and uncertainties, such as dilution to shareholders, the current valuation of Gossamer Bio still presents a favorable risk/reward opportunity.
Bears say
Gossamer Bio is facing risks and challenges that could impact its valuation and success in the long run. With a probability of success for their lead product at only 50% and potential dilution from a $200 million capital raise in 2027, the company's total firm value is estimated at only $1.1 billion. Additionally, there are multiple risks involved, including clinical development, commercialization, pricing, and dilution risks. A recent change in revenue and market models has also resulted in a lower price target of $1 per share and a shift to a Neutral rating from their previously held outlook of $6 per share. However, there is still potential for success if the FDA aligns with Gossamer's regulatory filing strategy and additional data shows objective improvements for PAH patients.
This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GOSS Analyst Forecast & Price Prediction
Start investing in GOSS
Order type
Buy in
Order amount
Est. shares
0 shares